AirWare Labs Files Patent Application for Revolutionary Oxygen Cannula Delivery System New Nasal Cannula System Will Resolve Common Patient Complaints and Improve the Effectiveness of Oxygen Therapy; Global Market Predicted to Reach $13.5 Billion by 2015 SCOTTSDALE, AZ -- (Marketwired) -- 07/09/14 -- AirWare Labs Corp. (OTCQB: AIRW) today announced the filing of a new patent application for a revolutionary oxygen cannula delivery system, expected to launch later this year. The system will feature a proprietary cannula design, fitted with disposable nasal dilators that diffuse the stream of oxygen as it enters the nasal passage and prevent the nasal dryness, irritation and discomfort commonly reported by cannula users. The nasal dilators also work to open the nasal passage and increase airflow by up to 60%, enhancing the overall effectiveness of oxygen therapy. Commonly prescribed for patients with chronic shortness of breath, sleep-related breathing disorders and chronic obstructive pulmonary disease (COPD), oxygen therapy has been widely provided through a nasal cannula system since the 1940s. Largely unchanged since its inception nearly 75 years ago, the traditional nasal cannula causes a myriad of patient complaints, including nasal passage dryness, irritation and failure to stay in place while the patient is asleep. In addition, the potential for contamination and infection from improperly cleaned cannulas is a pervading problem. According to the National Heart, Lung and Blood Institute, over 12 million people in the U.S. have been diagnosed with COPD and an additional 12 million are likely to have it without realizing it. A recent international survey found that worldwide prevalence ranged from 7%-9% (up to 640 million people). With home oxygen patients averaging two or three cannulas a month, an estimated 800 million cannulas are used annually for oxygen therapy alone. "With millions of people worldwide using nasal cannulas for oxygen therapy, it's surprising that the same issues with dryness and irritation have persisted since the 1940s," said Jeffrey Rassas, CEO of AirWare Labs. "We're very excited to bring to market a highly effective solution for these common complaints that will also significantly lower the risk of infection or contamination. The diffused air stream will greatly reduce dryness, and the inserts are designed to hold the cannula in place while the oxygen recipient is sleeping." The global market for respiratory care devices, including oxygen cannulas, is expected to reach $13.5 billion by 2015, according to market research and consulting company MarketsandMarkets. About AirWare Labs Corporation: AirWare Labs Corp., publicly traded as (OTCQB: AIRW), provides patented and innovative technology solutions for consumer products that promote better health through breathing and enhanced wellbeing. AirWare Labs' products are marketed under the brand name of AIR(R). AIR(R) products utilize an FDA approved medical grade material, molded as an intranasal Air Breathe dilator, to act as the delivery system. This AIR(R) microstructure enhances normal nasal airflow with every breath -- clinically proven to deliver up to 40% more oxygen. Some AIR(R) products are infused with essential oils with unique healing properties including antibacterial and therapeutic defense against airborne allergens, viruses and bacteria. AIR(R) Allergy and Travel products provide additional defense in the form of an integrated filter media from 3M to remove microscopic particles that carry viruses, allergens and bacteria. Other AIR(R) specialty products help provide performance enhancements and relief from congestion, insomnia, headaches, nausea, and snoring. For more product information, please visit: http://www.airwarelabs.com or company information visit: http://airwarelabscorp.com. Forward-Looking Statement: The statements in this press release regarding any implied or perceived benefits from the release by AirWare Labs Corp. of its products are forward-looking statements. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Media Contact: Jennifer Breitegan firstname.lastname@example.org Investor Relations: Keith Pinder Acorn Management 678-736-5682
AirWare Labs Files Patent Application for Revolutionary Oxygen Cannula Delivery System
Press spacebar to pause and continue. Press esc to stop.